OncoMatch/Clinical Trials/NCT05900882
SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
Is NCT05900882 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Selinexor and Bortezomib for multiple myeloma.
Treatment: Selinexor · Bortezomib · Lenalidomide · Dexamethasone — The purpose of this study is to evaluate the efficacy and safety of SVRd in NDMM patients presenting with extramedullary disease.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Demographics
Prior therapy
Lab requirements
Blood counts
ANC ≥ 1.0×10^9/L, HGB ≥ 75×10^9/L, PLT ≥ 50×10^9/L (≥50% of bone marrow nucleated cells are plasma cells)
Kidney function
creatinine clearance ≥ 30 ml/min
Liver function
ALT and AST < 3 times the upper limit of normal (ULN); serum bilirubin < 1.5 × ULN
Cardiac function
No active, unstable cardiovascular dysfunction: symptomatic ischemia; uncontrolled, clinically significant conduction abnormalities (except antiarrhythmic ventricular tachycardia); NYHA Class III-IV or LVEF <40%; myocardial infarction within 3 months before C1D1
ANC≥1.0*10^9/L, HGB≥75*10^9/L, PLT≥50*10^9/L (≥50% of bone marrow nucleated cells are plasma cells). Significant hepatic dysfunction (ALT and AST ≥ 3 times the upper limit of normal (ULN)). Serum bilirubin≥1.5 × ULN. creatinine clearance <30 ml/min. Active, unstable cardiovascular dysfunction: a. symptomatic ischemia; b. Uncontrolled, clinically significant conduction abnormalities (except antiarrhythmic ventricular tachycardia), but patients with first-degree atrioventricular block or asymptomatic left anterior bundle/right fascicular block cannot be excluded. c. New York Heart Association (NYHA) Class III - IV or left ventricular ejection fraction (LVEF) <40%; d. Myocardial infarction Within 3 months before C1D1.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05900882 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages